Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis
- Authors
- Caporali, Roberto; Allanore, Yannick; Alten, Rieke; Combe, Bernard; Durez, Patrick; Iannone, Florenzo; Nurmohamed, Mike T.; Lee, Sang Joon; Kwon, Taek Sang; Choi, Jean Soo; Park, Gahee; Yoo, Dae Hyun
- Issue Date
- Jan-2021
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Adalimumab; biosimilar; CT-P13; etanercept; infliximab; rheumatoid arthritis
- Citation
- EXPERT REVIEW OF CLINICAL IMMUNOLOGY, v.17, no.1, pp.85 - 99
- Indexed
- SCIE
SCOPUS
- Journal Title
- EXPERT REVIEW OF CLINICAL IMMUNOLOGY
- Volume
- 17
- Number
- 1
- Start Page
- 85
- End Page
- 99
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/8116
- DOI
- 10.1080/1744666X.2020.1858803
- ISSN
- 1744-666X
- Abstract
- Objectives
There are few comparative data for tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA).
Methods
Historical data for reference product/biosimilar intravenous infliximab, or adalimumab and etanercept, were pooled and compared with phase 3 study results for a subcutaneous (SC) formulation of the infliximab biosimilar CT-P13, in a systematic review and meta-analysis (PROSPERO: CRD42019149621).
Results
The authors identified 13 eligible controlled trials that randomized over 5400 participants to prespecified treatments of interest. Comparison with pooled historical data suggested a numerical advantage for CT-P13 SC over intravenous infliximab for almost every prespecified efficacy outcome evaluated, including Disease Activity Score in 28 joints (C-reactive protein/erythrocyte sedimentation rate), Clinical/Simplified Disease Activity Index scores, American College of Rheumatology responses, and multiple measures of disease remission and low disease activity; for the majority of outcomes, there was no overlap in 95% confidence intervals between groups. A numerical advantage for CT-P13 SC was also observed for safety outcomes (adverse events, infections, and discontinuations). Similar, but less marked, trends were observed for comparison with historical efficacy and safety data for adalimumab/etanercept.
Conclusion
CT-P13 SC offers an improved or similar benefit-to-harm ratio compared with infliximab (intravenous) and adalimumab/etanercept, for the treatment of moderate-to-severe RA.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/8116)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.